[HTML][HTML] T-cell metabolism in hematopoietic cell transplantation

HD Nguyen, S Kuril, D Bastian, XZ Yu - Frontiers in immunology, 2018 - frontiersin.org
HD Nguyen, S Kuril, D Bastian, XZ Yu
Frontiers in immunology, 2018frontiersin.org
Metabolism, including catabolism and anabolism, is a basic cellular process necessary for
cell survival. T lymphocytes have a distinct metabolism that can determine both fate and
function. T-cell activation depends on glycolysis to obtain materials and energy for
proliferation and effector function. Importantly, T cells utilize different metabolic processes
under different conditions and diseases. Allogeneic hematopoietic cell transplantation (allo-
HCT) is a classic immunotherapy for hematological malignancies; however, the …
Metabolism, including catabolism and anabolism, is a basic cellular process necessary for cell survival. T lymphocytes have a distinct metabolism that can determine both fate and function. T-cell activation depends on glycolysis to obtain materials and energy for proliferation and effector function. Importantly, T cells utilize different metabolic processes under different conditions and diseases. Allogeneic hematopoietic cell transplantation (allo-HCT) is a classic immunotherapy for hematological malignancies; however, the development of graft-versus-host disease (GVHD) is a major factor limiting the success of allo-HCT. T cells in the donor graft drive GVHD by mounting a robust immunological attack against recipient normal tissues. Hence, understanding T-cell metabolism after allo-HCT would provide potential metabolic targets for the control of GVHD and primary tumor relapse. The purpose of the current review is to highlight the key metabolic pathways involved in alloantigen-activated T cells and to discuss how manipulating these pathways can serve as potential new therapeutic strategies to induce immune tolerance after allo-transplantation. We will also summarize the recent progress in regulating T-cell metabolism in bone marrow transplantation by targeting novel metabolic regulators or immune checkpoint molecules.
Frontiers